Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

A Multifaceted Approach to Managing Cancer-Related Anxiety and Depression

August 27, 2025
By Boris M. Kiselev, MD
News
Video

Boris M. Kiselev, MD, explores evidence-based interventions for managing cancer-related anxiety and depression.

When addressing the psychological distress that often accompanies a cancer diagnosis, it is crucial for clinicians to consider a comprehensive toolkit that extends beyond conventional psychiatric medications.

While antidepressants and other pharmacological agents have a well-established role and are recommended by clinical guidelines, a truly holistic approach integrates a variety of evidence-based interventions. Boris M. Kiselev, MD, delves into the most effective methods for managing cancer-related anxiety and depression, highlighting the importance of psychotherapy as a foundational and lasting tool. He also discusses the significant benefits of integrative therapies and the critical need to address underlying medical conditions, offering a nuanced perspective on providing compassionate and effective care.

Kiselev is a consult liaison psychiatrist at Atrium Health Carolinas Medical Center, an assistant professor of the Psycho-Oncology Program in the Department of Supportive Oncology at Atrium Health Levine Cancer Institute, and an assistant professor in Internal Medicine.

Transcript:

[Many] times when people think about psycho-oncology, they’re thinking about antidepressants and what other things are out there. The idea that even though antidepressants are helpful and there’s a good evidence base to support their use for anxiety, depression, and cancer, and their use is recommended by guidelines, we still want to make sure we are using all the tools available to us. Psychology guidelines do recommend considering things like mindfulness-based interventions. This includes things like mindfulness-based stress reduction when that’s administered in a group or individual setting that has good, randomized trials supporting efficacy for anxiety and depression in patients dealing with cancer. There’s also good evidence for things like music therapy, relaxation interventions, for moderate quality evidence. There’s also good evidence for exercise being helpful for patients dealing with cancer, and that not only helps with both anxiety and depression, but also with sleep and fatigue. That’s supported by the American College of Sports Medicine Physical Activity Guidelines for adults dealing with cancer.

Additionally, there’s other integrative approaches too. You can consider things like Tai Chi, acupuncture, those all have lower quality evidence, but have been studied. Here at [Levine Cancer Institute], where I work, we have a robust integrative oncology department, and we’re often coordinating with them, referring patients to them, to get them connected with those types of treatment.

Other things to think about when managing these symptoms for patients, especially for those who are working in oncology is to make sure that we’re thinking about their medical comorbidities. For instance, thinking about patients who [receive] immunotherapy, considering endocrinopathies, it could be contributing to their psychiatric symptoms, or thinking about sleep disorders.

In terms of interventions, another thing I want to make sure I talk about as well is psychotherapy, and so the idea is that that’s going to help in many ways when we’re dealing with cancer, to process their experience. Talking about processing grief, learning tools and techniques can help them manage the symptoms day to day, develop coping skills, and help them to get just gain insight into themselves. The great thing about psychotherapy is that even after they complete the psychotherapy treatment that they’re doing, they’ll have those tools that they can take with them afterwards that will continue to be helpful to them in a longitudinal way.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, PT, DPT.
Related Content
Advertisement

The Nuclear Medicine Clarification Act seeks to increase transparency in reporting potentially high-dose extravasations in administering radiation.

H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice

Roman Fabbricatore
October 30th 2025
Article

The Nuclear Medicine Clarification Act seeks to increase transparency in reporting potentially high-dose extravasations in administering radiation.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma

Russ Conroy
October 29th 2025
Article

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Russ Conroy
October 24th 2025
Article

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.


Medical Conference Forum Latest Advances in Healthcare | © Purnomo-Adobe Stock

The Fellow's Playbook: How to Make the Most of Your First Oncology Meeting

Ariana Pelosci
October 21st 2025
Article

Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.

Related Content
Advertisement

The Nuclear Medicine Clarification Act seeks to increase transparency in reporting potentially high-dose extravasations in administering radiation.

H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice

Roman Fabbricatore
October 30th 2025
Article

The Nuclear Medicine Clarification Act seeks to increase transparency in reporting potentially high-dose extravasations in administering radiation.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma

Russ Conroy
October 29th 2025
Article

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Russ Conroy
October 24th 2025
Article

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.


Medical Conference Forum Latest Advances in Healthcare | © Purnomo-Adobe Stock

The Fellow's Playbook: How to Make the Most of Your First Oncology Meeting

Ariana Pelosci
October 21st 2025
Article

Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.